Microsulis microwave ablation system approved to show ETL safety
7 November 2011
Microsulis Medical Ltd has received approval to apply the ETL
safety mark to its Acculis microwave tissue ablation (MTA) system. The
company says the system has already been successfully commercialised in
Europe and North America, and is now being rolled out to the rest of the
The ETL Mark independently verifies compliance with international
safety standards, and is recognised world-wide. This accreditation
mark will now appear on Microsulis Medical’s Sulis VpMTA Generator,
which powers the Acculis range of microwave tissue ablation devices.
Stuart McIntyre, Microsulis Medical’s Chief Executive, said: “We
are pleased to apply this standard to our products. The ETL mark is
a trusted accreditation, which will underpin commercialisation of
our innovative technology in emerging markets.”
Microsulis Medical specialises in minimally invasive, soft tissue
ablation devices utilising microwave technology. The company’s
leading product is the Accu2i pMTA applicator, which is a
needle-like device that has been used by clinicians to treat tumours
of the liver, lung, kidneys and bone.
This device was CE-marked in February 2010, FDA 510(k) cleared in
August 2010, approved for use in Australia and New Zealand in August
2010, and gained a Health Canada licence in January 2011.
Source: Microsulis Medical